Increased bioavailability of type I IFNs is involved in diverse autoimmune diseases [10], and increased expression of type I IRGs has been detected in a subset of untreated MS patients [11], suggesting that some patients have augmented innate immunity, which is detected by monitoring type I IFN IRG expression in the absence of IFNβ injections. The gene discussed is IFNB1; the disease is myeloid sarcoma.